Zymeworks Inc. Announces Corporate Changes and Filings
Ticker: ZYME · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1937653
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filing
TL;DR
Zymeworks board shakeup, new execs, and comp changes filed today.
AI Summary
Zymeworks Inc. announced on November 16, 2025, a series of significant corporate events. These include the departure of directors, the election of new directors, the appointment of certain officers, and updates to compensatory arrangements for its officers. The company also provided a Regulation FD disclosure and reported on other events, alongside filing financial statements and exhibits.
Why It Matters
These changes in leadership and compensation structures can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- November 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 108 Patriot Drive, Suite A, Middletown, Delaware 19709 (address) — Principal executive offices
FAQ
What specific changes were made regarding the departure and election of directors?
The filing indicates the departure of directors and the election of new directors, but the specific names and details of these changes are not provided in this summary section.
Who are the newly appointed officers?
The filing mentions the appointment of certain officers, but their names and specific roles are not detailed in the provided text.
What are the key updates to the compensatory arrangements for officers?
The filing notes updates to compensatory arrangements for certain officers, but the specifics of these arrangements are not elaborated upon in this summary.
What is the significance of the Regulation FD disclosure?
A Regulation FD disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure.
What financial statements and exhibits were filed?
The filing indicates that financial statements and exhibits were included, but their specific content is not detailed in this summary.
Filing Stats: 1,042 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2025-11-18 06:03:57
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
- $125.0 million — which the Company may repurchase up to $125.0 million of the Company's common stock, par valu
- $299.4 m — expects its existing cash resources of $299.4 million, as of September 30, 2025, when c
Filing Documents
- d851143d8k.htm (8-K) — 30KB
- d851143dex991.htm (EX-99.1) — 29KB
- d851143dex992.htm (EX-99.2) — 14KB
- g851143g1118072056441.jpg (GRAPHIC) — 4KB
- 0001193125-25-285259.txt ( ) — 209KB
- zyme-20251116.xsd (EX-101.SCH) — 3KB
- zyme-20251116_lab.xml (EX-101.LAB) — 18KB
- zyme-20251116_pre.xml (EX-101.PRE) — 11KB
- d851143d8k_htm.xml (XML) — 4KB
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 18, 2025. 99.2 Press Release, dated November 18, 2025 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: November 18, 2025 By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair, President and Chief Executive Officer